Abstract:Mucosal barrier tissues and their mucosal associated lymphoid tissues (MALT) are attractive targets for vaccines and immunotherapies due to their roles in both priming and regulating adaptive immune responses. The upper and lower respiratory mucosae, in particular, possess unique properties: a vast surface area responsible for frontline protection against inhaled pathogens but also simultaneous tight regulation of homeostasis against a continuous backdrop of non-pathogenic antigen exposure. Within the upper and lower respiratory tract, the nasal and bronchial associated lymphoid tissues (NALT and BALT, respectively) are key sites where antigen-specific immune responses are orchestrated against inhaled antigens, serving as critical training grounds for adaptive immunity. Many infectious diseases are transmitted via respiratory mucosal sites, highlighting the need for vaccines that can activate resident frontline immune protection in these tissues to block infection. While traditional parenteral vaccines that are injected tend to elicit weak immunity in mucosal tissues, mucosal vaccines (i.e., that are administered intranasally) are capable of eliciting both systemic and mucosal immunity in tandem by initiating immune responses in the MALT. In contrast, administering antigen to mucosal tissues in the absence of adjuvant or costimulatory signals can instead induce antigen-specific tolerance by exploiting regulatory mechanisms inherent to MALT, holding potential for mucosal immunotherapies to treat autoimmunity. Yet despite being well motivated by mucosal biology, development of both mucosal subunit vaccines and immunotherapies has historically been plagued by poor drug delivery across mucosal barriers, resulting in weak efficacy, short-lived responses, and to-date a lack of clinical translation. Development of engineering strategies that can overcome barriers to mucosal delivery are thus critical for translation of mucosal subunit vaccines and immunotherapies. This review covers engineering strategies to enhance mucosal uptake via active targeting and passive transport mechanisms, with a parallel focus on mechanisms of immune activation and regulation in the respiratory mucosa. By combining engineering strategies for enhanced mucosal delivery with a better understanding of immune mechanisms in the NALT and BALT, we hope to illustrate the potential of these mucosal sites as targets for immunomodulation.

Host Functional Response to a Prototypic Orally Delivered Self-Replicating Vaccine Platform

Induction of Mucosal Immunity Through Systemic Immunization: Phantom or Reality?

Mechanistic Insight into the TH1-Biased Immune Response to Recombinant Subunit Vaccines Delivered by Probiotic Bacteria-Derived Outer Membrane Vesicles

Platform technology to deliver prophylactic molecules orally: an example using the Class A select agent Yersinia pestis

Mucosal Vaccine Development Based on Liposome Technology

Recombinant lactic acid bacteria as promising vectors for mucosal vaccination

Activation of B Cells by A Dendritic Cell-Targeted Oral Vaccine

Vaccine Strategies to Elicit Mucosal Immunity

Mucosal adjuvants

Parenteral vaccination strategies target protective immunity to the small and large intestine mucosa

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria

Progress on Lactococcus Lactis Expressing Heterologous Antigens As Live Mucosal Vaccines

Induction of protective immune responses at respiratory mucosal sites

Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?

Formulation Attributes Impact Immune Profile of an Oral and Thermostable COVID-19 Subunit Vaccine

Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo

Live-Attenuated Salmonella-Based Oral Vaccine Candidates Expressing PCV2d Cap and Rep by Novel Expression Plasmids as a Vaccination Strategy for Mucosal and Systemic Immune Responses against PCV2d

Mucoadhesive Vaccine Delivery Systems for the Oral Mucosa

ORAL ROUTE AS METHOD FOR IMMUNIZING AGAINST MUCOSAL PATHOGENS

Mucosal and systemic adjuvant activity of alphavirus replicon particles

Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake